258 related articles for article (PubMed ID: 31372961)
21. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Westhovens R; Wiland P; Zawadzki M; Ivanova D; Kasay AB; El-Khouri EC; Balázs É; Shevchuk S; Eliseeva L; Stanislavchuk M; Yatsyshyn R; Hrycaj P; Jaworski J; Zhdan V; Trefler J; Shesternya P; Lee SJ; Kim SH; Suh JH; Lee SG; Han NR; Yoo DH
Rheumatology (Oxford); 2021 May; 60(5):2277-2287. PubMed ID: 33230526
[TBL] [Abstract][Full Text] [Related]
22. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
[TBL] [Abstract][Full Text] [Related]
24. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
Fleischmann RM; Bock AE; Zhang W; Godfrey CM; Vranic I; Cronenberger C; Dokoupilová E
Rheumatol Ther; 2022 Jun; 9(3):839-850. PubMed ID: 35304684
[TBL] [Abstract][Full Text] [Related]
25. Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.
Yoo WH; Kang YM; Kim DW; Kang EH; Lee YA; Suh CH; Sung YK; Lee SH; Gu DH; Lee J; Choe JY
Rheumatol Ther; 2023 Apr; 10(2):329-341. PubMed ID: 36482248
[TBL] [Abstract][Full Text] [Related]
26. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
[No Abstract] [Full Text] [Related]
27. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.
Schulze-Koops H; Giacomelli R; Samborski W; Rednic S; Herold M; Yao R; Govoni M; Vastesaeger N; Weng HH
Clin Exp Rheumatol; 2015; 33(2):201-8. PubMed ID: 25664404
[TBL] [Abstract][Full Text] [Related]
30. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study.
Gharibdoost F; Salari AH; Salesi M; Ebrahimi Chaharom F; Mottaghi P; Hosseini M; Sahebari M; Nazarinia M; Mirfeizi Z; Shakibi M; Moussavi H; Karimifar M; Mowla K; Karimzadeh H; Anjidani N; Jamshidi A
Adv Ther; 2021 Feb; 38(2):1290-1300. PubMed ID: 33432540
[TBL] [Abstract][Full Text] [Related]
32. Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review.
Corominas H; Young D; Cummings JRF; Bouhnik Y; Armuzzi A; Thaci D; Kim J
Clin Drug Investig; 2023 Aug; 43(8):579-593. PubMed ID: 37615857
[TBL] [Abstract][Full Text] [Related]
33. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
[TBL] [Abstract][Full Text] [Related]
34. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
35. Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
Damjanov N; Kirvalidze N; Kurashvili N; Berti F; Steiger M; Sobierska J; Guenzi E; Otto H; Sattar A; Haliduola HN; Edwald E; Stroissnig H
Expert Opin Biol Ther; 2023; 23(8):781-789. PubMed ID: 36205514
[TBL] [Abstract][Full Text] [Related]
36. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH
Rheumatology (Oxford); 2017 Oct; 56(10):1771-1779. PubMed ID: 28957563
[TBL] [Abstract][Full Text] [Related]
37. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
Dehoratius RJ; Brent LH; Curtis JR; Ellis LA; Tang KL
Patient; 2018 Jun; 11(3):361-369. PubMed ID: 29427176
[TBL] [Abstract][Full Text] [Related]
38. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
39. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.
Borrás-Blasco J; Gracia-Pérez A; Casterá MD; Rosique-Robles JD; Abad J
Expert Opin Biol Ther; 2013 Aug; 13(8):1103-8. PubMed ID: 23675687
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Blauvelt A; Gordon KB; Lee P; Bagel J; Sofen H; Lockshin B; Soliman AM; Geng Z; Zhan T; Alperovich G; Stein Gold L
J Dermatolog Treat; 2022 Jun; 33(4):2085-2093. PubMed ID: 33947295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
